what's the buzz

what's the buzz

Fizzy drinks as harmful as drugs

It’s time to cut down on fizzy drinks. New research indicates that they are as bad for your teeth as drugs.

The study is based on the experience of woman in her 30s. She drank two litres of
diet fizzy drinks daily for three to five years and experienced tooth decay similar to that suffered by a 29-year-old methamphetamine addict and a 51-year-old habitual crack cocaine user, reports femalefirst.co.uk.

“The key part of this research is the fact the damage was caused by frequent consumption of fizzy drinks,” said Nigel Carter, chief executive of the British Dental Health Foundation.

Carter pointed out that frequent consumption of sugary drinks is unhealthy for mouth.

“Every time we eat or drink anything sugary, teeth are under attack for up to one hour. Saliva plays a major role in neutralising acid in the mouth, and it takes up to an hour for that to happen.

“If sugary items are constantly being consumed, the mouth is constantly under
attack and does not get the chance to recover,” explained Carter, adding: “The increase in consumption of sugary drinks is one of the key reasons for dental decay, particularly in children.”

Drug can delay ovarian cancer relapses: Study

A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released today found.

About 70 percent of patients with advanced ovarian cancer experience a relapse following surgery and chemotherapy and need to resume aggressive treatments. The deadly disease’s cure rate is just 20 to 25 percent.

German researchers found that the GlaxoSmithKlein drug pazopanib (Votrient) extended the median time to disease worsening to 17.9 months compared with 12.3 months for patients given a placebo in a phase III clinical trial.

“Our findings show that we finally have a drug that can maintain control over ovarian cancer growth achieved through initial treatments,” said lead author Andreas du Bois, a professor of gynaecologic oncology at Kliniken Essen Mitte in Germany.

“If pazopanib is approved for ovarian cancer, many patients will experience longer disease-free and chemotherapy-free periods. During this time, the patient keeps control over the disease instead of the disease having control over the patient’s life.”

An estimated 22,240 new cases of ovarian cancer are expected to be detected in the United States in 2013, and 14,030 women are expected to die from the disease this year.

There are currently no drugs approved in the United States as maintenance therapies for patients who’ve undergone treatment for advanced ovarian cancer, although Europe has approved Genentech’s bevacizumab (Avastin) for that use.
Pazopanib is an oral drug that blocks several targets involved in the growth of tumors and their blood vessels.

Ocean powered turbines for limitless electricity

VolturnUS - the first floating turbine intended to make electricity from the ocean’s winds - has been launched on the Penobscot River

This turbine is just a prototype and the final version will be eight times larger with each blade longer than the wingspan of a Boeing 747.

The plan is to put 150 of these type of turbines far out in the sea, where winds are stronger and more consistent than on land to have enough of these turbines to power Maine within 10 years, CBS News reported. Habib Dagher, who developed the technology at the University of Maine, said that in the Gulf of Maine the wind speed about 20 miles offshore is such that they have about 30 percent more energy every year than a turbine close to shores.  In Dagher’s lab, students tested the prototype models for every possible obstacle, and even created a mini “perfect storm,” with sustained winds up to 67 miles an hour.

The turbines, which could float on the ocean for up to 100 years, are going to be the first in the world that are made of composite material to avoid rust. They could float on the ocean for up to 100 years.